Cross Country Healthcare appoints Marvin Veizaga as CAO; James Redd and Phil Noe depart

CROSS COUNTRY HEALTHCARE INC

James V. Redd III ceases as SVP & Chief Accounting Officer effective March 10, 2026; no dispute with company.
Phil Noe ceases as Chief Information Officer effective March 10, 2026; departure not due to disagreement.
Marvin Veizaga, previously Group VP Corporate Controller, appointed SVP & CAO, reporting to CFO.
Veizaga receives base salary increase to $340,000; STI and LTI targets each at 50% of base salary.
No family relationships or material interest in transactions for new CAO.

item 5.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000929638-26-000955
form_type: 8-K
ticker: CCRN
cik: 0001141103
company_name: CROSS COUNTRY HEALTHCARE INC
filed_at: 2026-03-10T23:59:59+00:00
discovered_at: 2026-05-14T18:02:34.612174+00:00
generated_at: 2026-05-15T15:30:46.781483+00:00
sec_items: ["5.02", "9.01"]
event_type: leadership
sentiment: neutral
materiality_score: 0.35
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000929638-26-000955
json_url: https://secwatch.observer/filing/0000929638-26-000955.json
markdown_url: https://secwatch.observer/filing/0000929638-26-000955.md
text_url: https://secwatch.observer/filing/0000929638-26-000955.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1141103/000092963826000955/0000929638-26-000955-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1141103/000092963826000955/cc8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0000929638-26-000955

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.